Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer

Background: Esophageal cancer has a poor prognosis and currently ranks sixth in global cancer mortality rates. The ORIENT-15 trial showed sintilimab plus chemotherapy significantly improved survival when compared to chemotherapy alone. This study aimed to evaluate the cost-effectiveness of sintilima...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zhuo-Miao, Xu, Zhe, Zeng, Fan-Yuan, Tang, Zi-Qing, Zhou, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742528/
https://www.ncbi.nlm.nih.gov/pubmed/36518659
http://dx.doi.org/10.3389/fphar.2022.934275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742528/
https://www.ncbi.nlm.nih.gov/pubmed/36518659
http://dx.doi.org/10.3389/fphar.2022.934275

Ejemplares similares